ライフサイエンスコーパス: alpha(2) agonist

1 ubtype, after systemic administration of the alpha(2)-agonists 5-bromo-N-(4,5-dihydro-1H-imidazol-2-y

2 inephrine (NE), clonidine (CLON, a selective alpha2-agonist) and phenylephrine (PE, a selective alpha

3 fect profiles when compared with traditional alpha2 agonists, and may thereby allow for more widespre

4 Besides alpha2-agonists, apical uptake was inhibited by verapami

5 Dexmedetomidine, an alpha(2)-agonist available for ICU sedation, may reduce

6 ing the response to intravenous injection of alpha2-agonist before and after the infusion.

7 ttens received microinfusions (1 mul) of the alpha2 agonist clonidine (CLON; 1.32 nmol), and half rec

8 ,N-MePhe4, Gly-ol5]enkephalin (DAMGO) or the alpha2 agonist clonidine inhibited voltage-gated Ca2+ cu

9 of the alpha1-agonist phenylephrine and the alpha2-agonist clonidine.

10 cocaine CPP in the presence and absence of a alpha2-agonist (clonidine), beta-adrenergic receptor ant

11 e show that the alpha(2)-adrenergic agonist (alpha(2)-agonist) clonidine induced resistance to M. avi

12 The alpha2-agonist, clonidine, had a weak effect in LSI neur

13 eatment of HUVECs, but not neutrophils, with alpha2-agonists decreased transendothelial migration, wi

14 yet preliminary evidence indicates that the alpha(2) agonist dexmedetomidine may have distinct advan

15 duced unconsciousness and recovery using the alpha(2)-agonist dexmedetomidine.

16 The nonsubtype-selective alpha2 agonist dexmedetomidine completely blocked the co

17 both norepinephrine and the highly selective alpha2 agonist dexmedetomidine each reversed the VLPO de

18 ial alpha(1)-agonist, phenylephrine, or full alpha(2)-agonist, dexmedetomidine, indicated that the be

19 rine (alpha(1)-agonist) and dexmedetomidine (alpha(2)-agonist) during moderate rhythmic handgrip exer

20 rine (alpha(1)-agonist) and dexmedetomidine (alpha(2)-agonist) during rhythmic handgrip exercise (15%

21 to investigate the role of the alpha2aAR in alpha2 agonist-evoked analgesia and adrenergic-opioid sy

22 ernal cesium and external barium, opioid and alpha2 agonists had no effect at potentials more negativ

23 Alpha2 agonists have been in clinical use for decades, p

24 In recent years, alpha2 agonists have found wider application, particular

25 alpha2 agonists have similar potencies in stimulating Sr

26 nhibition of vas deferens contraction by the alpha2 agonist in alpha2A-AR knockout mice was only 42 +

27 phrine (an alpha1 agonist) and clonidine (an alpha2 agonist) in 10 healthy men during rhythmic handgr

28 To put the alpha2-agonists into clinical context, we will discuss t

29 ission at IPL and that brimonidine and other alpha2 agonists may protect RGCs under disease condition

30 The mutation also decreased alpha2-agonist-mediated spinal analgesia and blocked the

31 y before naloxone with clonidine (20 microg; alpha2 agonist), MK-801 (3 microg; noncompetitive NMDA a

32 Interestingly, alpha2-agonists prevented the TNF-alpha-mediated decreas

33 Guanabenz, an alpha2-agonist, prolonged baseline expiration and potent

34 alpha2 Agonists, such as brimonidine, have been shown to

35 neuroprotection of retinal ganglion cells by alpha2 agonists, such as brimonidine, in animal models o

36 Compelling evidence suggests that alpha2 agonists, such as brimonidine, protect retinal ga

37 The alpha2 agonists that are currently employed in anesthesi

38 Unexpectedly, alpha(2)-agonist treatment of mice heterozygous for the

39 ther in murine nor in human neutrophils upon alpha2-agonist treatment.

40 he NE-induced inhibition was mimicked by the alpha2-agonist, UK14,304, but not by the alpha1- or beta

41 (P < 0.05) and sensitivity (P < 0.05) to the alpha2 agonist UK14304 was lower in protein-, but not in

42 The hypotensive effect of alpha2 agonists was completely absent in alpha2A-deficie

43 eir hypnotic response to dexmedetomidine (an alpha2 agonist) was determined.

44 phrine (alpha1-agonist) and dexmedetomidine (alpha2-agonist) were assessed.

45 henylephrine (alpha1-agonist) and clonidine (alpha2-agonist) were assessed.

46 e (selective alpha1-agonist), and clonidine (alpha2-agonist) were determined in 10 young (aged 26+/-1

47 fter we will compare and contrast the use of alpha2-agonists with clinically available agents, and sp